Pinteon Therapeutics

OverviewSuggest Edit

Pinteon Therapeutics is a company that develops cancer therapeutics drugs intended to cure cis-trans isomerase. Its drugs are based out of biotechnological compounds focused on the discovery and development of therapeutics targeting Pin1 and related targets, enabling researchers to normalize aberrant disease processes and improve patient outcomes.
TypePrivate
Founded2014
Websitepinteon.com

Latest Updates

Employees (est.) (Oct 2021)8
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Pinteon Therapeutics

Michael Ahlijanian

Michael Ahlijanian

Chief Scientific Officer
Larry Altstiel

Larry Altstiel

Chief Medical Officer
Martin Jefson

Martin Jefson

Chief Executive Officer
Jeff Ives

Jeff Ives

Chairman
Show more

Pinteon Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2014

Pinteon Therapeutics total Funding

$20.5 m

Pinteon Therapeutics latest funding size

$17 m

Time since last funding

2 years ago

Pinteon Therapeutics investors

Pinteon Therapeutics's latest funding round in October 2019 was reported to be $17 m. In total, Pinteon Therapeutics has raised $20.5 m
Show all financial metrics

Pinteon Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Pinteon Therapeutics Online and Social Media Presence

Embed Graph

Pinteon Therapeutics Blogs

Pinteon Therapeutics Encouraged by Publication of Preclinical Study Supporting PNT001 for the Treatment of Tauopathies in Science Translational Medicine

Pinteon Therapeutics, a biotechnology company focused on protecting neuronal health by targeting neurotoxic forms of tau, is… The post Pinteon Therapeutics Encouraged by Publication of Preclinical Study Supporting PNT001 for the Treatment of Tauopathies in <em>Science Translational Medicine&lt…

Pinteon Extends Collaboration with Lonza for Manufacturing PNT001, a Novel Tau Antibody Targeting Alzheimer’s Disease and Traumatic Brain Injury

The agreement builds upon a long-term collaboration with the aim to provide drug substance of PNT001 for… The post Pinteon Extends Collaboration with Lonza for Manufacturing PNT001, a Novel Tau Antibody Targeting Alzheimer’s Disease and Traumatic Brain Injury appeared first on Pinteon Therapeutics.

Pinteon Therapeutics Announces $3 Million Award from Advanced Technology International to Support Phase 1 Study of PNT001 in Patients with Acute Traumatic Brain Injury

NEWTON, Mass. – June 17, 2021 – Pinteon Therapeutics, a biotechnology company focused on protecting neuronal health… The post Pinteon Therapeutics Announces $3 Million Award from Advanced Technology International to Support Phase 1 Study of PNT001 in Patients with Acute Traumatic Brain Injury appear…

Pinteon Therapeutics Announces First Patient Dosed in Phase 1 Study of PNT001 in Patients with Acute Traumatic Brain Injury

CAMBRIDGE, Mass. – April. 6, 2021 – Pinteon Therapeutics, a biotechnology company focused on protecting neuronal health… The post Pinteon Therapeutics Announces First Patient Dosed in Phase 1 Study of PNT001 in Patients with Acute Traumatic Brain Injury appeared first on Pinteon Therapeutics.

Pinteon Therapeutics Announces Promising Phase 1 Data for Novel Tau Antibody PNT001

Study showed PNT001 was well-tolerated at dose levels that may provide potential therapeutic effect PNT001 to be… The post Pinteon Therapeutics Announces Promising Phase 1 Data for Novel Tau Antibody PNT001 appeared first on Pinteon Therapeutics.

Pinteon Therapeutics Announces Upcoming Scientific Presentations

Chief Scientific Officer Michael Ahlijanian will present at CurePSP 2021 International Research Symposium Company to deliver two… The post Pinteon Therapeutics Announces Upcoming Scientific Presentations appeared first on Pinteon Therapeutics.

Pinteon Therapeutics Frequently Asked Questions

  • When was Pinteon Therapeutics founded?

    Pinteon Therapeutics was founded in 2014.

  • Who are Pinteon Therapeutics key executives?

    Pinteon Therapeutics's key executives are Michael Ahlijanian, Larry Altstiel and Martin Jefson.

  • How many employees does Pinteon Therapeutics have?

    Pinteon Therapeutics has 8 employees.

  • Who are Pinteon Therapeutics competitors?

    Competitors of Pinteon Therapeutics include Numab, OncoTherapy Science and Sonnet BioTherapeutics.